Please assess the completion status of the following clinical trial:

Trial Title: Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant of either gender aged ≥50 years~* Positive history of varicella or residence for \>30 years in a country with endemic VZV infection~* All females must be postmenopausal or have a negative serum or urine pregnancy test or acceptable method of birth control for three months after vaccination~* Participant having signed the informed consent form prior to any study procedure~Exclusion Criteria:~* Febrile within 72 hours prior to vaccination~* Prior history of Herpes Zoster clinically diagnosed by a physician~* Previously received a varicella or zoster vaccine~* Exposure to varicella or herpes-zoster within 4 weeks prior to vaccination~* Received any other live virus vaccine within 4 weeks prior to vaccination, or is expected to receive any other live virus vaccine during the study~* Received any inactivated vaccine within 2 weeks prior to vaccination, or is expected to receive any inactivated vaccine during the study~* Was treated with immunoglobulins or any blood products, other than autologous blood transfusion, given during the 5 months prior to vaccination or is expected to be treated during the study~* Taking any non topical antiviral therapy with activity against herpesviruses.~* On immunosuppressive therapy~* Known or suspected immune dysfunction caused by a medical condition, or any other cause~* History of hypersensitivity reaction or anaphylactoid reaction to any vaccine component, including gelatin or neomycin~* Known active tuberculosis~* Significant underlying illness preventing completion of the study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- All Enrolled (Type: EXPERIMENTAL): Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)

Based on this trial design, predict the completion outcome and termination type (if applicable).